C1-Esterase Inhibitor Human
Brand names: Cinryze · Active ingredient: Human C1-Esterase Inhibitor
In short: CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).
What is C1-Esterase Inhibitor Human used for?
CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).
C1-Esterase Inhibitor Human dosage
For intravenous use only.
Patient Population | Indication | Dose | Infusion Rate
Adults and adolescents(12 years old and above) | Routine prophylaxis against HAE attacks | 1,000 International Units (IU)One International Unit (IU) corresponds to the amount of C1 esterase inhibitor present in 1 mL of normal plasma as defined by the WHO international reference standard. Previously, the potency values were expressed in Units (U) and were relative to an in-house reference standard. A conversion factor of 0.83 can be used to recalculate the potency from U to IU, i.e., 100 U = 83 IU. The data that were generated with CINRYZE expressed in Units, are not converted to IU in the Prescribing Information. Intravenous (IV) every 3 or 4 days. For patients who have not responded adequately, doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered based on individual patient response. | 1 mL/min(10 min)
Pediatric patients(6 to 11 years old) | Routine prophylaxis against HAE attacks | 500 IU, Intravenous (IV) every 3 or 4 days. The dose may be adjusted according to individual response, up to 1,000 IU every 3 or 4 days. | 1 mL/min(5 min)
Protect CINRYZE from light prior to reconstitution.
A silicone-free syringe is recommended for reconstitution and administration of CINRYZE.
Inspect the reconstituted product for particulate matter prior to administration; do not use if particles are observed or if solution is turbid. The reconstituted solution is colorless to slightly blue.
Each vial of CINRYZE is for single use only. Promptly use any vial that has been entered and discard partially used vials in accordance with biohazard procedures. CINRYZE contains no preservative.
Do not mix CINRYZE with other materials.
Do not use if frozen.
Do not use after expiration date.
Use aseptic technique during the reconstitution procedure.
Bring the CINRYZE (powder) and Sterile Water for Injection, USP (diluent) to room temperature if refrigerated.
Remove caps from the CINRYZE and diluent vials.
Cleanse stoppers with an alcohol wipe or swab and allow them to dry prior to use.
Remove protective covering from the top of the Mix2Vial transfer device package. Do not remove the device from the package.
Note: Diluent vial must be accessed prior to the vial of CINRYZE to prevent loss of vacuum.
Reconstitution
Sterile Water for Injection USP is required for reconstitution. CINRYZE is supplied with Sterile Water for Injection USP .
One vial of reconstituted CINRYZE is used for a single 500 IU dose. Two vials of reconstituted CINRYZE are combined for a single 1,000 IU dose. …
How to take C1-Esterase Inhibitor Human — instructions & advice from the label
See FDA-approved patient labeling (Information for the Patient).
Inform patients to immediately report the following to their physician:
Signs of allergic-type hypersensitivity reactions including hives (itchy white elevated patches), tightness of the chest, wheezing, hypotension and anaphylaxis .
Advise patients to discontinue use of CINRYZE and contact their physicians if these symptoms occur.
Signs of a thromboembolic event including pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness, or weakness on one side of the body.
Advise patients with known risk factors for thromboembolic events that they may be at increased risk for these events.
Advise female patients to notify their physician if they become pregnant or intend to become pregnant during their routine prevention with CINRYZE.
Advise patients to notify their physician if they are breastfeeding or plan to breastfeed.
Based on their current regimen, advise patients to bring an adequate supply of CINRYZE for routine prevention when traveling. …
Warnings & precautions
Do not take this medicine if: CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.
Severe hypersensitivity reactions may occur. The signs and symptoms of hypersensitivity reactions may include the appearance of hives, urticaria, tightness of the chest, wheezing, hypotension and/or anaphylaxis experienced during or after injection of CINRYZE.
Consider treatment methods carefully because hypersensitivity reactions may have symptoms similar to HAE attacks.
In case of hypersensitivity, discontinue CINRYZE infusion and institute appropriate treatment. Have epinephrine immediately available for treatment of acute severe hypersensitivity reaction. .
Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 esterase inhibitor (human) products, including CINRYZE, following administration in patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives, certain androgens, morbid obesity, and immobility. Benefits of CINRYZE for routine prophylaxis of HAE attacks should be weighed against the risks of TE events in patients with underlying risk factors. Monitor patients with known risk factors for TE events during and after CINRYZE administration.
TE events have been reported following administration of a C1 esterase inhibitor (human) product when used off-label at higher than labeled doses1.
In an open-label trial further investigating the use of CINRYZE for prevention (n=146) of HAE attacks, 5 serious TE events (including myocardial infarction, deep vein thrombosis, pulmonary embolism and 2 events of cerebrovascular accident) occurred. Subjects had underlying risk factors for TE events. …
C1-Esterase Inhibitor Human side effects
The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Twenty-four subjects age 9 to 73 years old were evaluated in the randomized, placebo-controlled, crossover, routine prophylaxis trial. There were no serious adverse reactions in the randomized, placebo-controlled, crossover, routine prophylaxis trial.
Adverse reactions in the randomized, placebo-controlled, crossover, routine prophylaxis trial (n=24) that occurred in at least two subjects (≥8%) receiving CINRYZE are given in Table 2:
Adverse Reaction | Number of Adverse Reactions | Number of Subjects (N = 24)
Rash | 8 | 5
Headache | 4 | 4
Pruritus | 2 | 2
Vomiting | 2 | 2
In an open-label follow-on trial, 146 subjects age 3 to 82 years old received a median of 243.5 days of CINRYZE (maximum = 959 days). The most common adverse reaction observed was headache. No subjects were discontinued due to an adverse reaction. …
About this medicine
CINRYZE (C1 esterase inhibitor [human]) (Freeze-Dried Powder for Reconstitution) is a sterile, stable, lyophilized preparation of C1 esterase inhibitor derived from human plasma. CINRYZE is manufactured from human plasma purified by a combination of filtration and chromatographic procedures. CINRYZE potency is expressed by its C1 esterase inhibitor activity measured with a validated chromogenic assay. The potency of C1 esterase inhibitor is expressed in International Units (IU), which is related to the current WHO standard for C1 esterase inhibitor products. One International Unit (IU) corresponds to the amount of C1 esterase inhibitor present in 1 mL of normal plasma.
The specific activity of CINRYZE is 4.0 to 9.0 U/mg protein. The purity is ≥90% human C1 esterase inhibitor. Following reconstitution with 5 mL of Sterile Water for Injection, USP, each vial contains approximately 500 IU of functionally active C1 esterase inhibitor, pH 6.6 to 7.4, and an osmolality between 200 to 400 mosmol/kg. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d53a911f-070d-498a-8a61-baab72b9d0fe. Read the full official label on DailyMed.